image
OraSure Technologies, Inc. OSUR
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
Watchlist
$ 3.135
3.65 %
$ 234 M
Market Cap
-7.43
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Aug, 5, 2025.

The intrinsic value of one OSUR stock under the worst case scenario is HIDDEN Compared to the current market price of 3.13 USD, OraSure Technologies, Inc. is HIDDEN

OSUR Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Aug, 5, 2025.

The intrinsic value of one OSUR stock under the base case scenario is HIDDEN Compared to the current market price of 3.13 USD, OraSure Technologies, Inc. is HIDDEN

OSUR Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Aug, 5, 2025.

The intrinsic value of one OSUR stock under the best case scenario is HIDDEN Compared to the current market price of 3.13 USD, OraSure Technologies, Inc. is HIDDEN

OSUR Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart OSUR

image
1M 2%
6M -28.0%
1Y -38%
3Y --%
5Y -348%
All
$4.0$4.0$3.8$3.8$3.6$3.6$3.4$3.4$3.2$3.2$3.0$3.0$2.8$2.8$2.6$2.6$2.4$2.415 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 JulAug '25Aug '25
FINANCIALS
186 M REVENUE
-54.17%
Growth Rates
1Year -54.17%
3Years -7.35%
5Years 3.75%
7Years 1.53%
10Years 5.73%
-28.2 M OPERATING INCOME
-86.43%
Growth Rates
1Year -86.43%
3Years -34.35%
5Years -56.44%
7Years -7.89%
10Years -19.39%
-19.5 M NET INCOME
-36.34%
Growth Rates
1Year -36.34%
3Years 5.35%
5Years -16.77%
7Years -7.23%
10Years -15.50%
27.4 M OPERATING CASH FLOW
-80.67%
Growth Rates
1Year -80.67%
3Years 40.50%
5Years 22.80%
7Years -0.40%
10Years 13.78%
-39 M INVESTING CASH FLOW
-58.99%
Growth Rates
1Year -58.99%
3Years -92.15%
5Years -14.54%
7Years 12.11%
10Years -17.20%
-4.18 M FINANCING CASH FLOW
-38.14%
Growth Rates
1Year -38.14%
3Years -14.02%
5Years 2.26%
7Years -1.85%
10Years -25.60%
934 K REVENUE
-97.51%
Growth Rates
1Year -54.17%
3Years -7.35%
5Years 3.75%
7Years 1.53%
10Years 5.73%
-18.3 M OPERATING INCOME
-47.08%
Growth Rates
1Year -86.43%
3Years -34.35%
5Years -56.44%
7Years -7.89%
10Years -19.39%
-16 M NET INCOME
-48.60%
Growth Rates
1Year -36.34%
3Years 5.35%
5Years -16.77%
7Years -7.23%
10Years -15.50%
-19.7 M OPERATING CASH FLOW
-18103.67%
Growth Rates
1Year -80.67%
3Years 40.50%
5Years 22.80%
7Years -0.40%
10Years 13.78%
370 K INVESTING CASH FLOW
106.74%
Growth Rates
1Year -58.99%
3Years -92.15%
5Years -14.54%
7Years 12.11%
10Years -17.20%
-953 K FINANCING CASH FLOW
-758.56%
Growth Rates
1Year -38.14%
3Years -14.02%
5Years 2.26%
7Years -1.85%
10Years -25.60%
Balance Sheet OraSure Technologies, Inc.
image
Current Assets 333 M
Cash & Short-Term Investments 268 M
Receivables 23.8 M
Other Current Assets 41.6 M
Non-Current Assets 146 M
Long-Term Investments 28.3 M
PP&E 58.7 M
Other Non-Current Assets 59.4 M
55.82 %4.97 %8.68 %5.90 %12.24 %12.39 %Total Assets$479.7m
Current Liabilities 33.5 M
Accounts Payable 8.17 M
Short-Term Debt 2.17 M
Other Current Liabilities 23.1 M
Non-Current Liabilities 35.8 M
Long-Term Debt 12.4 M
Other Non-Current Liabilities 23.4 M
11.79 %3.13 %33.38 %17.94 %33.76 %Total Liabilities$69.3m
EFFICIENCY
Earnings Waterfall OraSure Technologies, Inc.
image
Revenue 186 M
Cost Of Revenue 110 M
Gross Profit 79.4 M
Operating Expenses 108 M
Operating Income -28.2 M
Other Expenses -8.75 M
Net Income -19.5 M
200m200m150m150m100m100m50m50m00(50m)(50m)186m(110m)79m(108m)(28m)9m(19m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
42.72% GROSS MARGIN
42.72%
Averages
1Year 42.72%
3Years 41.69%
5Years 46.94%
7Years 51.20%
10Years 55.34%
-15.20% OPERATING MARGIN
-15.20%
Averages
1Year -15.20%
3Years -2.78%
5Years -3.40%
7Years -0.47%
10Years 4.33%
-10.49% NET MARGIN
-10.49%
Averages
1Year -10.49%
3Years -0.63%
5Years -4.08%
7Years 0.22%
10Years 4.23%
-4.75% ROE
-4.75%
Averages
1Year -4.75%
3Years 0.92%
5Years -1.40%
7Years 0.80%
10Years 3.33%
-4.07% ROA
-4.07%
Averages
1Year -4.07%
3Years 1.00%
5Years -1.05%
7Years 0.85%
10Years 3.02%
-7.01% ROIC
-7.01%
Averages
1Year -7.01%
3Years -0.47%
5Years -3.02%
7Years -1.36%
10Years 1.69%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis OraSure Technologies, Inc.
image
150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -19.5 M
Depreciation & Amortization 10.9 M
Capital Expenditures -3.8 M
Stock-Based Compensation 11.9 M
Change in Working Capital 18.8 M
Others 3.35 M
Free Cash Flow 23.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets OraSure Technologies, Inc.
image
Wall Street analysts predict an average 1-year price target for OSUR of $4 , with forecasts ranging from a low of $4 to a high of $4 .
OSUR Lowest Price Target Wall Street Target
4 USD 27.59%
OSUR Average Price Target Wall Street Target
4 USD 27.59%
OSUR Highest Price Target Wall Street Target
4 USD 27.59%
Price
Max Price Target
Min Price Target
Average Price Target
55554444333322Sep '24Sep '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25May '25May '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26May '26May '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 5
6. Ownership
Insider Ownership OraSure Technologies, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
761 K USD 5
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
OraSure Appoints Anne Messing as Chief Commercial Officer BETHLEHEM, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing has joined OTI as Chief Commercial Officer. globenewswire.com - 1 day ago
OraSure Technologies: An Asymmetric Bet OraSure trades near cash value with minimal debt, reflecting excessive market pessimism and creating an asymmetric risk-reward opportunity. The company's future hinges on Sherlock's at-home STD test kit, with a high probability of FDA approval and strong market potential. Management is actively streamlining operations, divesting non-core assets, and positioning OraSure as an attractive acquisition target. seekingalpha.com - 1 week ago
OraSure to Announce Second Quarter 2025 Financial Results and Host Earnings Call on August 5th BETHLEHEM, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering second quarter 2025 financial results and certain business developments for 5 p.m. ET on August 5, 2025. globenewswire.com - 2 weeks ago
OraSure Technologies received takeover bid from industry entrepreneur, sources say Prominent healthcare entrepreneur Ron Zwanziger approached medical device maker OraSure Technologies with a takeover offer, three people familiar with the matter said, in what would mark more consolidation in the heavily fragmented diagnostic industry. reuters.com - 3 weeks ago
OraSure Launches Novel Blood Collection Device for Proteomic Research The device has the potential to transform proteomic discovery through extended protein stabilization and a simplified workflow for research The device has the potential to transform proteomic discovery through extended protein stabilization and a simplified workflow for research globenewswire.com - 3 weeks ago
Orasure Technologies: Multiple Shots To Deliver Value OSUR remains deeply undervalued, trading below liquidation value, with a robust, cash-rich, debt-free balance sheet providing downside protection. Key value drivers include a 20% share buyback, potential building sale, and new product launches both in-house and via partnerships. Operational improvements—cost reductions, automation, and product diversification—should support gross margins and future growth. seekingalpha.com - 2 months ago
OraSure Technologies, Inc. (OSUR) Q1 2025 Earnings Call Transcript OraSure Technologies, Inc. (NASDAQ:OSUR ) Q1 2025 Earnings Conference Call May 7, 2025 5:00 PM ET Company Participants Jason Plagman - VP of Investor Relations Carrie Eglinton Manner - President & Chief Executive Officer Ken McGrath - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Vijay Kumar - Evercore ISI Andrew Cooper - Raymond James Operator Good day, and thank you for standing by. Welcome to the OraSure Technologies, Inc. 2025 First Quarter Earnings Conference Call. seekingalpha.com - 2 months ago
OraSure Technologies (OSUR) Reports Q1 Loss, Tops Revenue Estimates OraSure Technologies (OSUR) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to earnings of $0.04 per share a year ago. zacks.com - 2 months ago
OraSure Technologies: Historically Cheap OraSure Technologies shares have dipped below $3 since my last writing, making shares even cheaper. Recent developments at the company include the acquisition of Sherlock Biosciences and the announcement of a $40 million share repurchase program. OSUR is enhancing business efficiency through cost cuts and aims to expand gross margins to 50% by year-end 2025, mitigating acquisition-related cash burn. seekingalpha.com - 3 months ago
OraSure to Announce First Quarter 2025 Financial Results and Host Earnings Call on May 7th BETHLEHEM, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2025 financial results and certain business developments for 5 p.m. ET on May 7, 2025. globenewswire.com - 3 months ago
OraSure Announces $40 Million Stock Repurchase Program BETHLEHEM, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (the “Company”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that its Board of Directors has authorized the repurchase of up to $40 million of its common stock over the next twenty-four months, which will be funded from cash on hand. globenewswire.com - 4 months ago
OraSure Technologies, Inc. (OSUR) Q4 2024 Earnings Call Transcript OraSure Technologies, Inc. (NASDAQ:OSUR ) Q4 2024 Results Conference Call February 25, 2025 5:00 PM ET Company Participants Jason Plagman - VP of Investor Relations Carrie Eglinton Manner - President & Chief Executive Officer Ken McGrath - Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Casey Woodring - JPMorgan Andrew Cooper - Raymond James Operator Welcome to the OraSure Technologies, Inc. 2024 Fourth Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 5 months ago
8. Profile Summary

OraSure Technologies, Inc. OSUR

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 234 M
Dividend Yield 0.00%
Description OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
Contact 220 East First Street, Bethlehem, PA, 18015 https://www.orasure.com
IPO Date Nov. 17, 1986
Employees 501
Officers Mr. Jason Michael Plagman Vice President of Investor Relations Ms. Kathleen Gallagher Weber Chief Product Officer Mr. Stefano Taucer General Counsel & Corporate Secretary Mr. David A. Rappaport C.F.A. Senior Vice President Corporate Development, Strategy & Integration Mr. Kenneth J. McGrath Chief Financial Officer Amy Steigerwalt Senior Vice President of Human Resources Ms. Michele Anthony Senior Vice President, Chief Accounting Officer, Controller & Assistant Secretary Ms. Carrie Eglinton Manner President, Chief Executive Officer & Director Mr. Rafal Iwasiow Ph.D. Vice President of Science, Innovation & Technology Mr. Zachary Wert Senior Vice President of Global Operations